Inventory

3 Months Ended

Mar. 31, 2023

Inventory Disclosure [Abstract]

Inventory

Inventory

Inventory consisted of the following (in thousands):

	March 31,		December 31,
	2023		2022
Raw materials	$	—	$	—
Work-in-process	3,640		2,994
Finished goods	209		26
Total inventory	$	3,849	$	3,020

The Company’s capitalized inventory consists of costs incurred subsequent to FDA approval of KRAZATI in December 2022. There were no inventory write downs during the three months ended March 31, 2023.